CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.57 per share a year ago.
CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX ) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin Hykes - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division John Edward Young - Canaccord Genuity Corp., Research Division Rohin Kirit Patel - JPMorgan Chase & Co, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Michael Vallie - Unidentified Company Operator Good afternoon, ladies and gentlemen.
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.65 per share a year ago.
CVRx, Inc. (CVRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has CVRx, Inc. ever had a stock split?
CVRx, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Kevin Hykes CEO | NASDAQ (NGS) Exchange | 126638105 CUSIP |
| US Country | 206 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CVRx, Inc. is a commercial-stage medical device company with a primary focus on the development, manufacturing, and commercialization of neuromodulation solutions aimed at treating cardiovascular diseases. Incorporated in the year 2000 and based in Minneapolis, Minnesota, CVRx has positioned itself at the forefront of the medical device industry by targeting a significant need within the cardiovascular disease treatment spectrum. Through its innovative approach, the company seeks to improve the quality of life for patients suffering from severe cardiovascular conditions by leveraging the potential of neuromodulation therapies. CVRx not only serves patients within the United States but also reaches a global audience, including Germany, through a combination of direct sales force, sales agents, and independent distributors, underscoring its commitment to addressing heart failure on a worldwide scale.
Products and Services
- Barostim
Barostim stands out as CVRx, Inc.’s flagship neuromodulation device, designed specifically to offer symptom improvement for patients dealing with heart failure with reduced ejection fraction, commonly referred to as systolic heart failure. By leveraging the advanced mechanism of neuromodulation, Barostim aims at enhancing the quality of life for those afflicted by this debilitating condition, marking a significant milestone in the treatment of heart failure. Its indication for this particular group of patients highlights the company's dedication to filling a critical gap in cardiovascular disease management through innovative technology.
Contact Information
